“The United States is the fourth country where our company operates. Starting operations in the U.S. is an integral part of our company’s development policies,” said Thomas Whitfield, CEO of Oxford BioLabs. “We decided to take this step first of all because of high local interest in our flagship product. We seek to better serve the needs of our customers and partners, and to provide them with even higher quality service. This means, for example, improving logistics, adapting to U.S. market regulatory standards, and establishing a special line for customer support.”
The company already serves American customers through its flagship product, TRX2. This molecular supplement for hair was developed by a prize-winning team of scientists from Oxford University.
Michael O’Leary, PhD, a key member of the product development and formulation team, has been appointed director of U.S. Operations, and will be responsible for developing the U.S. market and leading all operations.
In addition to the U.S., the company also carries out business and research activities in Great Britain, Germany, and Ukraine. Oxford BioLabs is currently working on expanding its range of products.